CMS Requires Expedited P&T Review For New Drugs In Six Protected Classes
Executive Summary
Part D drug plan pharmacy & therapeutics committees must make coverage decisions about new drugs or new indications within 90 days of their entry into the market in Medicare's six "all or substantially all" therapeutic categories, the Centers for Medicare & Medicaid Services states in its final formulary review 1guidelines for the 2007 contract year
You may also be interested in...
AHRQ Antidepressant Report May Put Pressure On CMS Formulary Guidelines
An Agency for Healthcare Research & Quality draft report finding no substantial efficacy difference among second-generation antidepressants could increase pressure on CMS' "all or substantially all" coverage policy for the class
AHRQ Antidepressant Report May Put Pressure On CMS Formulary Guidelines
An Agency for Healthcare Research & Quality draft report finding no substantial efficacy difference among second-generation antidepressants could increase pressure on CMS' "all or substantially all" coverage policy for the class
Part D Specialty Tier Should Be Reserved For Highest-Priced Drugs – BIO
Too many drugs will be subject to the maximum copay on Part D formularies if CMS allows plans to place all therapies with negotiated prices greater than $500 per month on the specialty tier, according to the Biotechnology Industry Organization